The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

A team of investigators from Dana-Farber Cancer Institute, The Broad Institute of MIT and Harvard, Google, and Columbia University have created an artificial intelligence model that can predict which ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.